top of page
pharma naming
The Readge blog
Looking to navigate the complex world of drug naming with more confidence? The Readge Blog offers sharp insights into regulatory naming—from INN and brand name approval to risk management and portfolio strategies.
You’ll find:
-
Practical tips for avoiding rejection by EMA, FDA and WHO
-
World wide examples of what works (and what doesn’t)
-
Strategies for building a strong, compliant name system
-
Articles and perspectives from experts around the world
Whether you're naming your first product or managing an entire portfolio, our blog gives you useful and instructive information.
Search
Biosimilars: Making the most of an “inexact” science
There’s no question that biosimilars are a revolution in life sciences. The development of these complex medications made from living...
pharmanaming.com by Readge consultants
3 min read
India to open drugs database to global regulators
India had exported medicines worth $15.2 billion (about Rs 97,000 crore) in 2014-15, an increase of 5% over the previous year’s figure....
pharmanaming.com by Readge consultants
2 min read
Indian government plans to set up Rs 500 crore VC fund for pharma industry
The Indian government plans to set up Rs 500 crore venture capital fund to boost domestic pharma industry and provide cheaper loans to...
pharmanaming.com by Readge consultants
2 min read
Top Trends in Biopharmaceutical Manufacturing: 2015
New cell-culture techniques, biomanufacturing formats, biological products, and the expansion of single-use applications are driving...
pharmanaming.com by Readge consultants
12 min read
The Coming Boom In Brain Medicines
Tony Coles could have had any job he wanted in the drug industry. In five years at the helm of cancer drug developer Onyx Pharmaceuticals...
pharmanaming.com by Readge consultants
9 min read
FDA issues draft guidance on nonproprietary naming of biosimilars
The FDA announced the availability of a draft guidance describing its proposal on the nonproprietary naming of biological products....
pharmanaming.com by Readge consultants
2 min read
Looking at the Recent FDA Biosimilar Guidelines
Small-molecule treatments are invaluable in providing symptomatic benefits for an array of illnesses. However, many serious conditions —...
pharmanaming.com by Readge consultants
6 min read
The secret of successful drug launches
About two-thirds of drug launches don’t meet expectations. Improving that record requires pharmaceutical companies to recognize the world...
pharmanaming.com by Readge consultants
1 min read
Why Don’t You Trust Generic Drugs as Much as Brand Name Medicines?
From www.peoplespharmacy.com Why don’t patients and their doctors trust generic drugs? Despite the fact that 84 percent of all...
pharmanaming.com by Readge consultants
2 min read
Double Trouble: Consumer awareness of look-alike names
From www.consumermedsafety.org Coming up with a name for a new medicine isn’t as easy as you think. Drug companies look for names that...
pharmanaming.com by Readge consultants
2 min read
Debate over naming of biosimilars intensifies ahead of WHO meeting
Healthcare payers are gearing up for huge savings from a slew of new biosimilars due to hit the market, but regulators are debating how...
pharmanaming.com by Readge consultants
9 min read
Indian drug exports under brand name to stay
MUMBAI: Pharma companies can breathe a tad easier. It is learnt that the government has dropped plans to enforce a ban on use of brand...
pharmanaming.com by Readge consultants
1 min read
Rapid pace of new approvals reflects accelerated review times by regulators
2015 was a good year for innovation in medicine with the U.S. Food and Drug Administration approving 45 novel drugs, four more than in...
pharmanaming.com by Readge consultants
2 min read
Delay of drug labeling policy can make generic drugs more dangerous
Several Americans who say they’ve been dangerously harmed by generic drugs — and were unaware of the risk because the drug maker did not...
pharmanaming.com by Readge consultants
4 min read
Turning science into value: Biopharma high performance business research
Biopharmaceutical companies focused on patient outcomes are enjoying more commercial success and outperforming their peers. Our research...
pharmanaming.com by Readge consultants
4 min read
Unspeakable Drug Names
Capecitabine (C15H22FN3O6) is an oncologically important chemotherapeutic prodrug. It has a trade name: Xeloda (pronounced zee-ló-da, I...
pharmanaming.com by Readge consultants
3 min read
Actelion creates Vaxxilon together with the Max Planck society
ALLSCHWIL, SWITZERLAND - 26 June 2015 - Actelion Ltd (SIX: ATLN) today announced the creation of a start-up, together with the Max Planck...
pharmanaming.com by Readge consultants
3 min read
Utrecht Centre of Excellence for Affordable Biotherapeutics
Utrecht University (The Netherlands) and the World Health Organisation (WHO) will work together to make affordable patent-free medicines...
pharmanaming.com by Readge consultants
2 min read
Actavis changes name in Allergan
From www.dddmag.com – February 18, 2015 Actavis will change the company name after the completed acquisition of Allergan. Actavis, the...
pharmanaming.com by Readge consultants
1 min read
Pharma seminar in Mumbai
The Dutch Consulate and Globrands' pharmanaming.com cordially invite you to an informative and eye opening seminar, on how to make your...
pharmanaming.com by Readge consultants
2 min read
bottom of page